DEF 14A

Company

Denali Therapeutics Inc.

Filed

April 22, 2020

Period of Report

June 3, 2020

Accession Number

0001714899-20-000041

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →